Fresh on the heels of announcing a multibillion-dollar development pact with GlaxoSmithKline, Merck KGaA is showing off its blueprint for a big expansion of its R&D operations in Billerica, outside of Boston.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,000+ biopharma pros who read Endpoints News by email every day.Free Subscription